Fennec Pharmaceuticals Inc. SEC filings FENC
Fennec Pharmaceuticals Inc. has 853 filings in SEC EDGAR's recent list, going back to Dec 10, 2002. Its latest annual report, Form 10-K, was filed on Mar 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 17, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Jun 11, 2026 | — |
| S-8 | Employee stock plan registration | Mar 5, 2026 | — |
| S-8 | Employee stock plan registration | Nov 18, 2025 | — |
| 424B5 | Prospectus supplement | Nov 18, 2025 | — |
| 424B5 | Prospectus supplement | Nov 17, 2025 | — |
| 424B5 | Prospectus supplement | Nov 13, 2025 | — |
| 424B7 | Filing | Mar 15, 2024 | — |
| S-3 | Shelf registration | Nov 9, 2023 | — |
| 424B3 | Prospectus | Dec 15, 2022 | — |
| S-3 | Shelf registration | Dec 1, 2022 | — |
| S-3 | Shelf registration | Oct 30, 2020 | — |
| 424B5 | Prospectus supplement | Oct 30, 2020 | — |
| 424B5 | Prospectus supplement | May 1, 2020 | — |
| 424B5 | Prospectus supplement | Apr 29, 2020 | — |
| S-8 | Employee stock plan registration | Jun 26, 2019 | — |
| 424B3 | Prospectus | Apr 20, 2018 | — |
| POS AM | Filing | Apr 13, 2018 | — |
| 424B5 | Prospectus supplement | Dec 11, 2017 | — |
| FWP | Free writing prospectus | Dec 7, 2017 | — |
| 424B5 | Prospectus supplement | Dec 7, 2017 | — |
| S-3 | Shelf registration | Oct 24, 2017 | — |
| S-8 | Employee stock plan registration | Oct 24, 2017 | — |
| 424B3 | Prospectus | Sep 19, 2017 | — |
| S-1/A | Amended registration statement | Aug 31, 2017 | — |
| S-1 | Registration statement | Aug 10, 2017 | — |
| S-1 | Registration statement | May 12, 2015 | — |
| 424B3 | Prospectus | May 14, 2014 | — |
| S-1 | Registration statement | May 9, 2014 | — |
| 424B3 | Prospectus | Apr 21, 2014 | — |
| POS AM | Filing | Apr 9, 2014 | — |
| POS AM | Filing | Apr 9, 2014 | — |
| 424B3 | Prospectus | Apr 4, 2013 | — |
| POS AM | Filing | Apr 1, 2013 | — |
| 424B3 | Prospectus | Nov 14, 2011 | — |
| POS AM | Filing | Nov 8, 2011 | — |
| 424B3 | Prospectus | Aug 26, 2011 | — |
| 424B3 | Prospectus | Feb 22, 2011 | — |
| 424B3 | Prospectus | Feb 14, 2011 | — |
| S-1/A | Amended registration statement | Feb 9, 2011 | — |
| S-1 | Registration statement | Nov 12, 2010 | — |
| POS AM | Registration statement amendment no. 1 | Mar 30, 2010 | — |
| S-8 POS | Registration statement amendment no. 1 | Mar 30, 2010 | — |
| S-8 POS | Registration statement amendment no. 1 | Mar 30, 2010 | — |
| S-8 POS | Registration statement amendment no. 1 | Mar 30, 2010 | — |
| F-3/A | Registration statement amendment no. 1 | Mar 30, 2010 | — |
| S-8 | Employee stock plan registration | Jun 29, 2007 | — |
| 424B3 | Prospectus | Jun 22, 2006 | — |
| F-3 | Shelf registration (foreign issuer) | Jun 5, 2006 | — |
| S-8 | Employee stock plan registration | Jul 15, 2005 | — |
| S-8 | Employee stock plan registration | Jan 27, 2005 | — |
Showing 50 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- FENC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Research Triangle Park, NC
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1211583
- Former names
- ADHEREX TECHNOLOGIES INC (until Aug 14, 2014)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.